New Developments in Clinical Research

Interested in learning more about the latest clinical research into issues such as infections, nontuberculous mycobacteria (NTM), and nutrition and gastrointestinal health? To find out what new, cutting-edge studies are addressing these cystic fibrosis-related complications, watch the following interviews with some of the leading researchers in these areas.


Jennifer Taylor-Cousar, M.D., M.S.C.S., ATSF, who is co-director and CF Therapeutics Development Network (TDN) director of the adult cystic fibrosis program at National Jewish Health in Denver, discusses clinical research to improve treatment for cystic fibrosis infections. This research includes trials to determine the appropriate length of time to administer intravenous (IV) antibiotics during a pulmonary exacerbation as well as new approaches to treat drug-resistant bacteria.

Nontuberculous Mycobacteria

Dave Nichols, M.D., medical director of the TDN Coordinating Center at Seattle Children's Hospital, updates us on new developments in research on nontuberculous mycobacteria (NTM), which has become an increasing problem for people with CF. Dr. Nichols talks about how clinicians determine whether to treat people with CF who culture NTM, and what researchers are doing to better understand this bacteria to improve treatment.

Nutrition and Gastrointestinal Health

Meghana N. Sathe, M.D., associate professor of pediatrics and co-director of the pediatric CF center at the University of Texas Southwestern Medical Center/Children's Health, explains why people with CF can have problems with getting proper nutrition and experience gastrointestinal (GI) issues. She also discusses the GI Wellness study (now called the GALAXY study), which is being conducted by doctors from the Developing Innovative Gastroenterology Specialty Training program (DIGEST) to gauge which GI symptoms affect people with CF the most, so that researchers can prioritize them for further study.

Preclinical Research and New Technologies

In this video, Michael P. Boyle, M.D., senior vice president of therapeutics development at the Foundation, talks about the latest preclinical research (a stage of research immediately before clinical trials) and why the Foundation is pursuing new technologies, such as gene editing and gene therapy. To learn more, you can visit the Foundation's Drug Development Pipeline, which enables you to track the progress of potential CF therapies as they move from the preclinical stage to each clinical trial phase.

CFTR Modulators

In this video, George M. Solomon, M.D., assistant professor of medicine and director of the adult CF program at the University of Alabama at Birmingham, explains what the cystic fibrosis transmembrane conductance regulator (CFTR) protein does and why correcting and restoring function to the CFTR protein is a central focus of CF research. Dr. Solomon also provides updates on new developments in CFTR modulators, including the triple-combination therapies that could help people with CF who have a wider range of CFTR mutations.

Mucociliary Clearance

Scott H. Donaldson, M.D., associate professor of medicine and director of the adult CF center at the University of North Carolina, discusses why people with CF have trouble clearing mucus from their lungs and why this causes problems. He talks about what types of drugs are being developed to improve mucociliary clearance, the process of breaking down and moving mucus out of the lungs.


Deepika Polineni, M.D., M.P.H., assistant professor of internal medicine at the University of Kansas Medical Center and associate adult program director of the University of Kansas CF Care Center, discusses why inflammation is a problem for people with CF and the strategies researchers are using to develop anti-inflammatories.

Share this Page